Potential Drug Target and Biomarker for PNMA8B (KIAA1183) (G57469)

Target Name: PNMA8B

NCBI ID: G57469

PNMA8B

Potential Drug Target and Biomarker for PNMA8B (KIAA1183)

Peroxisome-nitrogenase A8 (PNMA8) is a key enzyme involved in the detoxification of xenobiotics, such as polycyclic aromatic hydrocarbons (PAHs) and polycyclic aromatic carbonates (PACs), which are environmental toxins. The PNMA8 gene has been identified as a potential drug target for the development of therapeutic agents against various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. In this article, we will discuss the potential drug target and biomarker for PNMA8B (KIAA1183), a gene that has been implicated in the development and progression of various diseases.

The PNMA8 Enzyme

Peroxisome-nitrogenase A8 is an enzyme that is involved in the detoxification of a wide variety of xenobiotics, including PAHs and PACs. PAHs and PACs are derived from polycyclic aromatic hydrocarbons (PAHs) and polycyclic aromatic carbonates (PACs), respectively. These molecules are found in various environmental sources, such as water, soil, and air. The PNMA8 enzyme uses ATP and NAD+ as co-factors to convert these xenobiotics into less toxic metabolites.

The Importance of PNMA8

The PNMA8 enzyme is crucial for the detoxification of xenobiotics, which are toxic compounds that can cause harm to the human body. Many studies have suggested that exposure to environmental xenobiotics can lead to the development of various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. The PNMA8 enzyme plays a critical role in the detoxification of these xenobiotics, which may have implications for the development and progression of these diseases.

Drug Targeting

The PNMA8 gene has been identified as a potential drug target for the development of therapeutic agents against various diseases. The PNMA8 enzyme has been shown to be involved in the development and progression of cancer, neurodegenerative disorders, and autoimmune diseases. Several studies have suggested that inhibition of the PNMA8 enzyme may be an effective way to treat these diseases.

Biomarker

One of the challenges in drug development is the development of biomarkers that can predict the effectiveness of a drug. In the case of PNMA8B (KIAA1183), a potential drug target for the development of therapeutic agents against various diseases, a biomarker may be used to assess the effectiveness of a drug or to identify biomarkers that are associated with the development of these diseases.

Conclusion

In conclusion, PNMA8B (KIAA1183) is a gene that has been implicated in the development and progression of various diseases. The PNMA8 enzyme is involved in the detoxification of xenobiotics, which are derived from polycyclic aromatic hydrocarbons and polycyclic aromatic carbonates. The potential drug target and biomarker for PNMA8B makes it an attractive target for the development of therapeutic agents against various diseases. Further research is needed to fully understand the role of PNMA8B in the development and progression of these diseases.

Protein Name: PNMA Family Member 8B

The "PNMA8B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PNMA8B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets